HOME › Research Insight › Product Development & Commercialization is the Key Strategy Adopted by Leading Market Players to Foster Growth in the Global HLA Typing for Transplant Market
Product Development & Commercialization is the Key Strategy Adopted by Leading Market Players to Foster Growth in the Global HLA Typing for Transplant Market
In 2015, the global HLA typing for transplant market was dominated by Thermo Fischer Scientific, Inc. (U.S.), Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), and Bio-Rad Laboratories, Inc. (U.S.). These top five market players jointly accounted for a share of ~89.3% of the global HLA typing for transplant market in 2015. Other key players present in the global HLA typing for transplant market included Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others.
Thermo Fisher Scientific, Inc. (U.S.) held the leadership in the global HLA typing for transplant market in 2015. The company has a broad product portfolio of HLA typing products, including state-of-the-art instruments (such as Ion PGM Dx system, QuantStudio Dx Real-time PCR system, 3500 Dx Genetic Analyzers, Veriti Dx PCR Thermal Cycler, and 7500 fast Dx Real-time PCR system), reagents (such as serological assay kits, molecular typing kits, antibody detection kits, and Secore HLA Class I & II sequence-based typing kits), consumables (vials and bottles), and software. The company has a strong geographic presence in more than 50 countries across the globe, with key markets in the U.S., China, Germany, and the U.K. It focuses mainly on strategic acquisitions to gain state-of-art HLA typing technologies for transplant and to strengthen its market position. In line with this strategy, the market has witnessed several significant acquisitions by Thermo Fisher Scientific in the last three years—such as its acquisition of Affymetrix Inc. (January 2016), Life Technologies Corporation (February 2014), and One lambda, Inc. (November 2013). Thermo Fisher Scientific also focuses on the development of technologically advanced HLA-based transplant diagnostic instruments and supporting reagents as a key growth strategy.
Immucor, Inc. (U.S.) held the second position in the global market in 2015. The company has a strong foothold in the HLA typing for transplant market with a broad range of automated instruments for antibody screening and analysis, semi-automated systems for serological assays, standalone systems, and reagents for molecular and non-molecular assay procedures (including HLA typing products). In order to strengthen its current position and gain a larger share in the HLA typing for transplant market, the company aggressively focuses on inorganic growth strategies such as acquisitions and collaborations. It acquired several key market players in the HLA typing for transplant segment, including Sirona Genomics (U.S.), Organ-i, Inc. (U.S.), and the LIFECODES business segment from Hologic, Inc. (U.S.). This helped the company to increase its market share and strengthen its position in the HLA typing for transplant market. Additionally, Immucor, Inc. collaborated with Sirona Genomics (U.S.) to provide funding for the development and commercialization of Sirona’s HLA typing products. This helped strengthen the company’s technological base in the HLA typing for transplant market.
In the global HLA typing for transplant market, leading players adopted various growth strategies such as new product launches and product development; agreements, collaborations, and partnerships; mergers and strategic acquisitions; and geographic expansions. Market players adopted these strategies to develop innovative and technologically advanced HLA typing products, expand their product portfolios, enter emerging markets, and increase their market shares. In addition to the top five market players, companies such as Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.) adopted agreements, collaborations, partnerships, new product launches, and product development as their key growth strategies to widen their product offerings and strengthen their pipeline development capabilities in the fast-growing HLA typing for transplant market.
HLA Typing for Transplant Market by Technology (SSO-PCR, SSP-PCR, NGS, Sanger’s Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) - Forecast to 2021
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India